WO1993001802A1 - Composition pour la liberation prolongee et controlee d'une substance medicamenteuse peptidique et procede pour sa preparation - Google Patents

Composition pour la liberation prolongee et controlee d'une substance medicamenteuse peptidique et procede pour sa preparation Download PDF

Info

Publication number
WO1993001802A1
WO1993001802A1 PCT/CH1992/000146 CH9200146W WO9301802A1 WO 1993001802 A1 WO1993001802 A1 WO 1993001802A1 CH 9200146 W CH9200146 W CH 9200146W WO 9301802 A1 WO9301802 A1 WO 9301802A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
water
salt
copolymer
insoluble
Prior art date
Application number
PCT/CH1992/000146
Other languages
English (en)
French (fr)
Inventor
Frédéric Heimgartner
Piero Orsolini
Original Assignee
Asta Medica Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Aktiengesellschaft filed Critical Asta Medica Aktiengesellschaft
Priority to RU93004902A priority Critical patent/RU2103994C1/ru
Priority to BR9205375A priority patent/BR9205375A/pt
Priority to PL92298504A priority patent/PL169387B1/pl
Priority to CZ1993660A priority patent/CZ287585B6/cs
Priority to HU9301186A priority patent/HU218203B/hu
Priority to SK382-93A priority patent/SK280612B6/sk
Priority to UA93004548A priority patent/UA35569C2/uk
Priority to CH882/93A priority patent/CH683592A5/fr
Publication of WO1993001802A1 publication Critical patent/WO1993001802A1/fr
Priority to KR1019930700851A priority patent/KR930702018A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides

Definitions

  • composition for the sustained and controlled release of a peptide drug substance and process for its preparation
  • the subject of the invention is a composition intended for the prolonged and controlled release of a peptide drug substance of formula (I):
  • R 3 denotes P-Pal or D-Trp.
  • pep ides are analogs of LHRH and can be advantageously used in the. therapeutic treatment of hormone-dependent disorders.
  • amino acids are conventionally designated and have the L configuration; D-Nal denotes D-3- (2-naphthyl) - alanine and D-Pal denotes D-3- (3-pyridyl) - alanine.
  • composition according to the invention is in the form of microspheres of biodegradable polymeric material incorporating a water-insoluble salt of the peptide of formula (I).
  • a composition incorporating for example at least 5% by weight of insoluble salt relative to the weight of biodegradable polymeric material, can release the peptide of formula (I) in a controlled manner for several days after its parenteral administration in humans or The animal.
  • the invention also relates to a process for the preparation of a composition as defined above. It consists in first converting a salt of the peptide of formula (I) soluble in water into a salt of insoluble peptide in water, then in suspending said salt of peptide in suspension in a solution of biodegradable polymer material, to converting said suspension into an oil-in-water type ulsion and finally isolating the microspheres of biodegradable polymer after transfer of the oil-in-water emulsion in an excess of aqueous medium.
  • the invention offer to the skilled person a particularly unique way to take advantage of relative solubilities of the ingredients set in play, more particularly solvents and "non-solvents" involved.
  • Said method is characterized by the fact that: a. converting a salt of the water-soluble peptide of formula (I) into a salt of a water-insoluble peptide; b. said water-insoluble peptide salt is suspended in an organic medium containing the biodegradable polymeric material in the dissolved state; vs. dispersing said organic suspension in an aqueous medium forming the continuous phase of the resulting emulsion; d. said emulsion is transferred to an excess of aqueous medium and finally the microspheres thus obtained are separated from the liquid phase.
  • the first phase of the process consists in converting, using the usual techniques, the salt of water-soluble peptide into a salt of water-insoluble peptide.
  • water soluble is meant a peptide salt having a water solubility greater than or equal to 0.1 mg / ml at 25 ° C, preferably greater than or equal to 1.0 mg / ml.
  • insoluble in water is meant a peptide salt having a solubility in water - less than or equal to 0.1 mg / ml at 25 ° C. Salts of peptides such as pamoate, tannate, stearate or palmitate meet this definition.
  • biodegradable polymer a polylactide, a polyglycolide, a copolymer of lactic and glycolic acids is used.
  • PLGA copolymers of lactic and glycolic acids
  • L- or D copolymers of L- or D, L- lactic acid containing from 45 to 90% (mole%) of units lactic acid, respectively 55 to 10% (mole%) of glycolic acid units.
  • an organic solvent such as methylene chloride is used, for example, in all cases a solvent behaving like a "non-solvent" for the salt of peptide retained.
  • the salt is suspended in the organic solution of polymeric material, the latter is incorporated into a predetermined amount of an aqueous medium, most generally water with the addition of a surfactant. appropriate.
  • an aqueous medium most generally water with the addition of a surfactant. appropriate.
  • the aim is the rapid formation of a homogeneous emulsion, of the oil-in-water type, said aqueous medium serving as a continuous phase.
  • Various factors are involved in the preparation of such an emulsion, which in turn conditions the size or structure of the microspheres resulting from the process.
  • One of the factors to be considered is the rate of addition of the organic solution to the aqueous medium; another may be the temperature or the stirring speed or the energy of dispersion (sonication), the latter parameter influencing in particular the size of the final microspheres.
  • aqueous medium generally water.
  • Such an operation aims to amplify the hardening of the embryonic microspheres formed in the emulsion, by extraction of the organic solvent still present in said microspheres.
  • This operation also aims at simultaneously removing the traces still present of surfactant which could remain in the mass of polymer during final hardening.
  • water is a "non-solvent" both for the biodegradable polymer material, such as PLGA for example, and for the peptide salt present in said microspheres. This situation favors the necessary extraction of residual solvent from the polymer, CH 2 CI 2 for example.
  • the hardened microspheres are collected in accordance with the usual techniques, for example centrifugation, filtration or decantation. Washes, purifications and drying are carried out in the same way.
  • One of the advantages of the process of the invention is that it makes it possible to obtain microspheres the size of which can be controlled with precision, this control operating essentially during the preparation of the emulsion (speed of stirring by example).
  • Another advantage is the particularly high peptide loading rate which is can obtain, 5, 10 or even 20% weight or more depending on the case.
  • the yield of incorporation of the peptide or peptide salt is particularly high; this is in particular due to the prior conversion of the water-soluble peptide salt into a water-insoluble salt.
  • microspheres obtained in accordance with the process of the invention from the abovementioned ingredients are then used, after adequate sterilization, for the preparation of suspensions intended for administration by the parenteral route, for example an intramuscular or subcutaneous injection.
  • the resulting suspension was then discharged all at once in 500 ml of 0.075% methoxycellulose solution in water and stirring of the mixture continued for approximately. 90 min at room temperature (stirring speed 900 rpm). The evolution of the emulsion is followed periodically, on average every 30 minutes, by taking a sample and examining the microspheres present under the microscope.
  • the PLGA microspheres were isolated from the reaction mixture and purified by a succession of centrifugations alternating with washing with H 2 O, and finally filtered and dried under reduced pressure. 1.61 g (rdt 80%) of PLGA microspheres were thus collected, comprising more than 94% of particles with a diameter of less than 100 microns (max. At 55-85 microns).
  • microspheres thus obtained were then subjected to sterilization by gamma rays and suspended in an appropriate sterile vehicle.
  • In vivo tests assay of blood testosterone level in male rats confirm the regular release of the active substance.
  • PLGA microspheres 1.70 g (85% yield).
  • Example 1 The process of Example 1 was repeated, using 3 g of LHRH analog acetate of formula
  • microspheres of polymer material were obtained having the same characteristics as above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/CH1992/000146 1991-07-22 1992-07-15 Composition pour la liberation prolongee et controlee d'une substance medicamenteuse peptidique et procede pour sa preparation WO1993001802A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
RU93004902A RU2103994C1 (ru) 1991-07-22 1992-07-15 Композиция в форме микросфер для пролонгированного и контролируемого высвобождения пептидного лекарственного вещества
BR9205375A BR9205375A (pt) 1991-07-22 1992-07-15 Composicao para a liberacao prolongada e controlada de uma substancia medicamentosa peptidica e processo para a sua preparacao
PL92298504A PL169387B1 (pl) 1991-07-22 1992-07-15 Sposób wytwarzania preparatu o przedluzonym i kontrolowanym uwalnianiu peptydowejsubstancji leczniczej PL PL PL PL PL PL PL
CZ1993660A CZ287585B6 (cs) 1991-07-22 1992-07-15 Prostředek k prodlouženému a kontrolovanému uvolňování léčivé peptidové látky a způsob jeho přípravy
HU9301186A HU218203B (hu) 1991-07-22 1992-07-15 Készítmény gyógyhatású peptidek késleltetett és szabályozott leadására, és eljárás a készítmények és az azt tartalmazó parenterális szuszpenzió előállítására
SK382-93A SK280612B6 (sk) 1991-07-22 1992-07-15 Zmes na predĺžené a kontrolované uvolňovanie lieči
UA93004548A UA35569C2 (uk) 1991-07-22 1992-07-15 Композиція для пролонгованого і контрольованого вивільнення пептидної лікарської речовини і спосіб її одержання, спосіб приготування суспензії, що призначена для парентерального введення
CH882/93A CH683592A5 (fr) 1991-07-22 1992-07-15 Composition pour la libération prolongée et contrôlée d'une substance médicamenteuse peptidique et procédé pour sa préparation.
KR1019930700851A KR930702018A (ko) 1991-07-22 1993-03-22 펩타이드-함유 약제의 서방출 및 제어방출 조성물 및 이의 제조방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH2178/91-0 1991-07-22
CH2178/91A CH683149A5 (fr) 1991-07-22 1991-07-22 Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Publications (1)

Publication Number Publication Date
WO1993001802A1 true WO1993001802A1 (fr) 1993-02-04

Family

ID=4227716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH1992/000146 WO1993001802A1 (fr) 1991-07-22 1992-07-15 Composition pour la liberation prolongee et controlee d'une substance medicamenteuse peptidique et procede pour sa preparation

Country Status (40)

Country Link
US (2) US5445832A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP2842736B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR930702018A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1054543C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) AT408609B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU651711B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (2) BE1005696A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9205375A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2074320C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (2) CH683149A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ287585B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE4223282A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK176219B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE03014B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2037621B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (2) FI105318B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR2679450B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB2257973B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (2) GR1001446B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP920229A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU218203B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (2) IE69967B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL102590A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (2) IT1259891B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (2) LU88151A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9204268A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (2) NL194577C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO304057B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ243643A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH31564A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL169387B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT100713B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2103994C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (2) SE512670C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI9200152B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK280612B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW260610B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA35569C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1993001802A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (2) ZA925485B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030084B2 (en) 1999-06-19 2006-04-18 Nobex Corporation Drug-oligomer conjugates with polyethylene glycol components
US7084114B2 (en) 2001-06-04 2006-08-01 Nobex Corporation Mixtures of insulin drug-oligomer comprising polyalkylene glycol
US7084121B2 (en) 2001-06-04 2006-08-01 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7381702B2 (en) 2001-02-15 2008-06-03 Biocon Limited Methods of treating diabetes mellitus
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US9101596B2 (en) 2004-07-19 2015-08-11 Biocon Limited Cation complexes of insulin compound conjugates, formulations and uses thereof

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
CA2123144A1 (en) 1993-05-10 1994-11-11 David Bodmer Stabilisation of pharmacologically active compounds in sustained release compositions
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
KR0162872B1 (ko) * 1996-04-01 1998-12-01 김은영 용매추출법을 이용한 생분해성 고분자 미립구의 개선된 제조방법 및 이를 이용한 국소염증 질환 치료용 미립구의 제조방법
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
US6465015B1 (en) * 1998-02-24 2002-10-15 Arch Chemicals, Inc. Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
CA2324254C (en) * 1998-03-18 2005-01-04 University Technology Corporation Sustained-release composition including amorphous polymer
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
JP2002521343A (ja) * 1998-07-23 2002-07-16 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス 水溶性ペプチドのカプセル化
US6270700B1 (en) 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
US6682724B2 (en) 1999-02-23 2004-01-27 Arch Chemcials, Inc. Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US6317623B1 (en) * 1999-03-12 2001-11-13 Medrad, Inc. Apparatus and method for controlling contrast enhanced imaging procedures
WO2000054797A2 (en) 1999-03-17 2000-09-21 Novartis Ag Pharmaceutical compositions comprising tgf-beta
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
US6899898B2 (en) 2000-12-21 2005-05-31 Nektar Therapeutics Induced phase transition method for the production of microparticles containing hydrophobic active agents
IL160570A0 (en) * 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
KR100885070B1 (ko) * 2002-05-08 2009-02-25 재단법인서울대학교산학협력재단 Ｐｌｇａ에 특이적으로 부착하는 올리고 펩타이드
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
KR20050086948A (ko) * 2002-12-27 2005-08-30 디오벡스, 인코포레이티드 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SI1594517T1 (sl) 2003-01-28 2007-10-31 Microbia Inc Sestavki za zdravljenje gastrointestinalnih motenj
EP1605894A2 (en) * 2003-03-05 2005-12-21 PR Pharmaceuticals Oxytocin controlled release formulations and methods of using same
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
CN105820160B (zh) 2003-11-05 2019-02-12 萨可德生物科学公司 细胞粘着调节剂
AU2005325213B2 (en) 2004-08-04 2010-10-07 Evonik Operations Gmbh Methods for manufacturing delivery devices and devices thereof
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006078903A1 (en) * 2005-01-21 2006-07-27 Matthews Richard H Radiosensitizer formulations comprising nitrohistidine derivatives
AU2006241072A1 (en) * 2005-04-25 2006-11-02 Amgen Inc. Biodegradable peptide sustained release compositions containing porogens
EP3195861A1 (en) 2005-05-17 2017-07-26 SARcode Bioscience Inc. Compositions and methods for treatment of dry eye disorders
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
JP2009516003A (ja) * 2005-11-15 2009-04-16 バクスター・インターナショナル・インコーポレイテッド リポキシゲナーゼ阻害剤の組成物
KR20140133968A (ko) 2005-12-22 2014-11-20 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
WO2007089739A2 (en) * 2006-01-27 2007-08-09 Stryker Corporation Low pressure delivery system and method for delivering a solid and liquid mixture into a target site for medical treatment
KR100722607B1 (ko) * 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
RU2326655C1 (ru) * 2006-11-09 2008-06-20 Федеральное государственное учреждение "48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации" Способ инкапсулирования белоксодержащих веществ в микросферы из сополимера полилактид-полигликолид
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
US8211905B1 (en) 2007-05-22 2012-07-03 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US10166181B2 (en) * 2007-06-06 2019-01-01 Debiopharm Research & Manufacturing Sa Slow release pharmaceutical composition made of microgranules
PT2203181T (pt) 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
CA2958665C (en) 2007-10-19 2021-03-02 Sarcode Bioscience Inc. Compositions and methods for treatment of diabetic retinopathy
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
US8080562B2 (en) * 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
US11612579B2 (en) 2009-03-09 2023-03-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CN102665698A (zh) 2009-12-23 2012-09-12 迪菲安特制药有限责任公司 可用于治疗心血管疾病的联合组合物
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012151343A1 (en) 2011-05-04 2012-11-08 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
US9585896B2 (en) 2012-04-04 2017-03-07 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
PT2851085T (pt) * 2012-05-14 2019-10-11 Teijin Pharma Ltd Composição proteica esterilizada por radiação
JP6607780B2 (ja) 2012-07-25 2019-11-20 サルコード・バイオサイエンス・インコーポレイテッド Ｌｆａ−１阻害剤およびその多形
HK1218629A1 (zh) 2013-02-25 2017-03-03 Bausch Health Ireland Limited 用於结肠清洁的鸟苷酸环化酶受体激动剂
EP3578170A1 (en) 2013-02-28 2019-12-11 Basf As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3054969B1 (en) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
JP6784696B2 (ja) 2015-04-28 2020-11-11 プロノヴァ バイオファーマ ノルゲ エーエス 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis
JOP20200068A1 (ar) 2017-09-26 2020-04-27 Nanomi B V طريقة لتحضير جسيمات دقيقة بواسطة تقنية مستحلب مزدوج
EP3720431B1 (en) 2017-12-06 2024-10-30 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2491351A1 (fr) * 1980-10-06 1982-04-09 Stolle Res & Dev Procede de microcapsulation
FR2620621A1 (fr) * 1987-09-21 1989-03-24 Bpd Biopharm Dev Ltd Composition pharmaceutique pour la liberation soutenue et controlee de polypeptides insolubles dans l'eau
FR2649319A1 (fr) * 1989-07-07 1991-01-11 Sandoz Sa Formulations a liberation prolongee de peptides solubles dans l'eau
DE4023134A1 (de) * 1989-07-28 1991-01-31 Debiopharm Sa Verfahren zur herstellung einer pharmazeutischen zubereitung in form von mikropartikeln

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1972-01-26 1977-01-27
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4341767A (en) * 1980-10-06 1982-07-27 Syntex Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
CH672887A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1987-10-14 1990-01-15 Debiopharm Sa
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
EP0471036B2 (en) * 1989-05-04 2004-06-23 Southern Research Institute Encapsulation process
CH681425A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-11-14 1993-03-31 Debio Rech Pharma Sa
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2491351A1 (fr) * 1980-10-06 1982-04-09 Stolle Res & Dev Procede de microcapsulation
FR2620621A1 (fr) * 1987-09-21 1989-03-24 Bpd Biopharm Dev Ltd Composition pharmaceutique pour la liberation soutenue et controlee de polypeptides insolubles dans l'eau
FR2649319A1 (fr) * 1989-07-07 1991-01-11 Sandoz Sa Formulations a liberation prolongee de peptides solubles dans l'eau
DE4023134A1 (de) * 1989-07-28 1991-01-31 Debiopharm Sa Verfahren zur herstellung einer pharmazeutischen zubereitung in form von mikropartikeln

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INT. J. PEPTIDE RES. vol. 35, no. 6, 1990, NEW-ORLEANS USA pages 557 - 565 CSERNUS V.J. ET AL 'RELEASE OF PEPTIDES FROM SUSTAINED DELIVERY SYSTEMS (MICROCAPSULES AND MICROPARTICLES) IN VIVO' VOIR PAGE 558 "MATERIALS AND METHODS" *
PROC. NATL. ACAD. SCI. USA vol. 88, no. 3, Février 1991, NEW-ORLEANS USA pages 844 - 848 KORKUT E. ET AL 'INHIBITION OF GROWTH OF EXPERIMENTAL PROSTATE CANCER WITH SUSTAINED DELIVERY SYSTEMS (MICROCAPSULES AND MICROGRANULES) OF THE LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONIST SB-75' *
THE JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY vol. 37, no. 6, 20 Décembre 1990, pages 1061 - 1067 SCHALLY A.V. ET AL 'ANTITUMOR EFFECT OF ANALOGS OF LHRH AND SOMATOSTATIN: EXPERIMENTAL AND CLINICAL STUDIES' *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6943148B1 (en) 1998-08-14 2005-09-13 Nobex Corporation Methods for delivering therapeutics across blood-barrier and for altering receptor binding affinity
US6956051B1 (en) 1998-08-14 2005-10-18 Nobex Corporation Enkephalin conjugates
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7030084B2 (en) 1999-06-19 2006-04-18 Nobex Corporation Drug-oligomer conjugates with polyethylene glycol components
US7381702B2 (en) 2001-02-15 2008-06-03 Biocon Limited Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7084121B2 (en) 2001-06-04 2006-08-01 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7084114B2 (en) 2001-06-04 2006-08-01 Nobex Corporation Mixtures of insulin drug-oligomer comprising polyalkylene glycol
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7470663B2 (en) 2001-06-04 2008-12-30 Biocon Limited Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7611864B2 (en) 2001-09-07 2009-11-03 Biocon Limited Proinsulin polypeptide-oligomer conjugates
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US9101596B2 (en) 2004-07-19 2015-08-11 Biocon Limited Cation complexes of insulin compound conjugates, formulations and uses thereof
US9102758B2 (en) 2004-07-19 2015-08-11 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof

Also Published As

Publication number Publication date
SE512670C2 (sv) 2000-04-17
GR1002548B (el) 1997-01-28
CA2074322A1 (en) 1993-01-23
PL298504A1 (en) 1994-01-10
US5445832A (en) 1995-08-29
NL194576C (nl) 2002-08-05
ES2037621A1 (es) 1993-06-16
GB2257973B (en) 1996-02-28
FI105318B (fi) 2000-07-31
LU88150A1 (fr) 1993-02-15
ITBS920092A1 (it) 1994-01-21
GB2257909A (en) 1993-01-27
JPH05221855A (ja) 1993-08-31
IE922367A1 (en) 1993-01-27
BE1005696A3 (fr) 1993-12-21
HRP920229A2 (en) 1996-04-30
SE9202213L (sv) 1993-01-23
RU2103994C1 (ru) 1998-02-10
CA2074320C (en) 1999-04-06
PT100712A (pt) 1993-10-29
AU651711B2 (en) 1994-07-28
GB2257973A (en) 1993-01-27
ZA925486B (en) 1993-04-28
FR2680109B1 (fr) 1994-09-02
ES2037621B1 (es) 1994-02-01
NL194576B (nl) 2002-04-02
MX9204268A (es) 1994-03-31
US5637568A (en) 1997-06-10
GB9215480D0 (en) 1992-09-02
CN1054543C (zh) 2000-07-19
NO304057B1 (no) 1998-10-19
ZA925485B (en) 1993-04-28
FI923320L (fi) 1993-01-23
FR2679450B1 (fr) 1995-06-09
FI106925B (fi) 2001-05-15
SI9200152A (en) 1993-03-31
ATA148992A (de) 1997-06-15
HUT64234A (en) 1993-12-28
IE922366A1 (en) 1993-01-27
DE9219084U1 (de) 1997-09-25
HU9301186D0 (en) 1993-07-28
CN1070344A (zh) 1993-03-31
CA2074320A1 (en) 1993-01-23
NO304136B1 (no) 1998-11-02
ITBS920093A0 (it) 1992-07-21
IL102590A0 (en) 1993-01-14
IL102591A0 (en) 1993-01-14
PT100712B (pt) 1999-07-30
DE4223284C2 (de) 1997-07-31
IL102590A (en) 1997-07-13
JP3600252B2 (ja) 2004-12-15
CH683592A5 (fr) 1994-04-15
PT100713A (pt) 1993-08-31
SI9200152B (sl) 1998-06-30
AU2043692A (en) 1993-01-28
CZ66093A3 (en) 1994-01-19
NO922886L (no) 1993-01-25
FR2680109A1 (fr) 1993-02-12
GB2257909B (en) 1996-01-10
IT1259892B (it) 1996-03-28
IT1259891B (it) 1996-03-28
ES2050070B1 (es) 1994-10-01
CA2074322C (en) 2003-04-08
CZ287585B6 (cs) 2000-12-13
CH683149A5 (fr) 1994-01-31
SK280612B6 (sk) 2000-05-16
UA35569C2 (uk) 2001-04-16
HU218203B (hu) 2000-06-28
GR1001446B (el) 1993-12-30
GR920100323A (el) 1993-05-24
IE69967B1 (en) 1996-10-16
JP2842736B2 (ja) 1999-01-06
NL9201309A (nl) 1993-02-16
DE4223284A1 (de) 1993-01-28
NL9201310A (nl) 1993-02-16
AT408609B (de) 2002-01-25
SE9202212L (sv) 1993-01-23
LU88151A1 (fr) 1993-02-15
DK176218B1 (da) 2007-02-26
ATA148892A (de) 2001-06-15
IL102591A (en) 1997-06-10
DK93892A (da) 1993-01-23
JPH06172208A (ja) 1994-06-21
SK38293A3 (en) 1993-08-11
NZ243643A (en) 1993-10-26
NO922885L (no) 1993-01-25
PH31564A (en) 1998-11-03
IE71199B1 (en) 1997-02-12
GB9215479D0 (en) 1992-09-02
NO922885D0 (no) 1992-07-21
NL194577C (nl) 2002-08-05
FR2679450A1 (fr) 1993-01-29
BE1005697A5 (fr) 1993-12-21
KR930702018A (ko) 1993-09-08
DK176219B1 (da) 2007-02-26
FI923320A0 (fi) 1992-07-21
DK93992D0 (da) 1992-07-21
FI923321A0 (fi) 1992-07-21
ITBS920093A1 (it) 1994-01-21
NO922886D0 (no) 1992-07-21
NL194577B (nl) 2002-04-02
AU652844B2 (en) 1994-09-08
BR9205375A (pt) 1994-03-08
EE03014B1 (et) 1997-08-15
ITBS920092A0 (it) 1992-07-21
PT100713B (pt) 1999-07-30
SE512609C2 (sv) 2000-04-10
DK93892D0 (da) 1992-07-21
FI923321L (fi) 1993-01-23
DK93992A (da) 1993-01-23
PL169387B1 (pl) 1996-07-31
DE4223282A1 (de) 1993-01-28
AU2043792A (en) 1993-01-28
SE9202213D0 (sv) 1992-07-21
TW260610B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-10-21
ES2050070A1 (es) 1994-05-01
AT403348B (de) 1998-01-26
SE9202212D0 (sv) 1992-07-21

Similar Documents

Publication Publication Date Title
BE1005696A3 (fr) Composition pour la liberation prolongee et controlee d'une substance medicamenteuse peptidique et procede pour sa preparation.
EP0585151B1 (fr) Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues
EP1450766B1 (fr) Microspheres biodegradables a liberation prolongee et leur procede de preparation
BE1006143A3 (fr) Sels de peptides avec des polyesters carboxytermines.
EP0608207B1 (fr) Compositions pharmaceutiques contenant des nanocapsules
EP0170540B1 (fr) Procédé de préparation de microcapsules biodégrables à base de sérumalbumine
CA2102186C (fr) Nanoparticules ayant un temps de capture par le systeme reticulo endothelial allonge
WO1999048517A1 (fr) Compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
FR2649319A1 (fr) Formulations a liberation prolongee de peptides solubles dans l'eau
WO1998047489A1 (fr) Compositions presentant une liberation prolongee et leur procede de preparation
CH661206A5 (fr) Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
EP0523183A1 (fr) Microspheres, leur procede de preparation et leur utilisation.
FR2571617A1 (fr) Procede pour la microencapsulation par separation de phases de substances medicamenteuses hydrosolubles
CH665558A5 (en) Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage
FR2830448A1 (fr) Microspheres biodegradables a liberation prolongee et leur procede de preparation
WO2005009415A2 (fr) Nouveau procede de preparation de microparticules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BR CH CS HU KR PL RU

WWE Wipo information: entry into national phase

Ref document number: 1019930700851

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV1993-660

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 38293

Country of ref document: SK

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: UA

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: UA

WWP Wipo information: published in national office

Ref document number: PV1993-660

Country of ref document: CZ

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: BY

WWG Wipo information: grant in national office

Ref document number: PV1993-660

Country of ref document: CZ